Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas

Nuclear Medicine and Biology

Volumn 38, Issue 1, 2011, Pages 103-112

  Nestor, Marika ^a   Sundström, Magnus ^a   Anniko, Matti ^a   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alpha radiation; Astatine; Cetuximab; EGFR; Radioimmunotherapy; Squamous cell carcinoma

Indexed keywords

CD44V6 ANTIGEN; CETUXIMAB; CHIMERIC MONOCLONAL ANTIBODY U36 AT 211; EPIDERMAL GROWTH FACTOR RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALPHA RADIATION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; DRUG MECHANISM; DRUG UPTAKE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; PROTEIN PROTEIN INTERACTION; RADIATION EXPOSURE; RADIATION PROTECTION; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ASTATINE; BIOLOGICAL TRANSPORT; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; RADIOIMMUNOTHERAPY; TUMOR STEM CELL ASSAY;

EID: 78650975238     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.06.014     Document Type: Article

References (63)

1. Khazaie K., Schirrmacher V., Lichtner R.B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993, 12:255-274.
2. Grandis J.R., Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993, 53:3579-3584.
3. Zips D., Krause M., Yaromina A., Dorfler A., Eicheler W., Schutze C., et al. Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. J Pharm Pharmacol 2008, 60:1019-1028.
4. Santini J., Formento J.L., Francoual M., Milano G., Schneider M., Dassonville O., et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991, 13:132-139.
5. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7(Suppl 4):2-8.
6. Grandis J.R., Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004, 102:37-46.
7. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8:3-9.
8. Tsatsanis C., Spandidos D.A. The role of oncogenic kinases in human cancer (Review). Int J Mol Med 2000, 5:583-590.
9. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl 4):S9-S15.
10. Pivot X., Magne N., Guardiola E., Poissonnet G., Dassonville O., Francoual M., et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 2005, 41:320-327.
11. Hitt R., Ciruelos E., Amador M.L., Benito A., Sanchez J.J., Ballestin C., et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005, 41:453-460.
12. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006, 107:1207-1218.
13. Dutta P.R., Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007, 254:165-177.
14. Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997, 89:341-343.
15. Perez-Soler R., Donato N.J., Shin D.M., Rosenblum M.G., Zhang H.Z., Tornos C., et al. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 1994, 12:730-739.
16. Modjtahedi H., Dean C. Monoclonal antibodies to the EGF receptor act as betacellulin antagonists. Biochem Biophys Res Commun 1996, 221:625-630.
17. Cruz J.J., Ocana A., Del Barco E., Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007, 18:421-430.
18. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53:4637-4642.
19. Fan Z., Lu Y., Wu X., Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994, 269:27595-27602.
20. Prewett M., Rockwell P., Rockwell R.F., Giorgio N.A., Mendelsohn J., Scher H.I., et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996, 19:419-427.
21. Diaz Miqueli A., Blanco R., Garcia B., Badia T., Batista A.E., Alonso R., et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 2007, 26:423-431.
22. Dittmann K., Mayer C., Fehrenbacher B., Schaller M., Raju U., Milas L., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005, 280:31182-31189.
23. Dent P., Reardon D.B., Park J.S., Bowers G., Logsdon C., Valerie K., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999, 10:2493-2506.
24. Akimoto T., Hunter N.R., Buchmiller L., Mason K., Ang K.K., Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999, 5:2884-2890.
25. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000, 6:2166-2174.
26. Bianco C., Bianco R., Tortora G., Damiano V., Guerrieri P., Montemaggi P., et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000, 6:4343-4350.
27. Milas L., Mason K., Hunter N., Petersen S., Yamakawa M., Ang K., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6:701-708.
28. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:1935-1940.
29. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
30. Pignon J.P., le Maitre A., Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007, 69:S112-114.
31. Caudell J.J., Sawrie S.M., Spencer S.A., Desmond R.A., Carroll W.R., Peters G.E., et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008, 71:676-681.
32. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
33. Krause M., Gurtner K., Deuse Y., Baumann M. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int J Radiat Biol 2009, 85:943-954.
34. Carlsson J., Forssell Aronsson E., Hietala S.O., Stigbrand T., Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003, 66:107-117.
35. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002, 43:693-713.
36. Colnot DR, Nieuwenhuis EJC, Kuik DJ, Leemans R, Dijkstra J, Snow GB, et al. Clinical significance of micrometastatic cells detected by E48 (ly-6D) reverse transcriptase-polymerase chain reaction in bone marrow of head and neck cancer patients. Clin Cancer Res 2004, 10:7827-7833.
37. Breitz H.B. How far have we come with solid (nonhematologic) tumor radioimmunotherapy? J Nucl Med 2000, 41:2011-2014.
38. Zalutsky M.R., Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000, 6:1433-1455.
39. Tijink B.M., Neri D., Leemans C.R., Budde M., Dinkelborg L.M., Stigter-van Walsum M., et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006, 47:1127-1135.
40. van Gog F.B., Brakenhoff R.H., Stigter-van Walsum M., Snow G.B., van Dongen G.A. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 1998, 77:13-18.
41. Nestor M. Effect of cetuximab treatment in squamous cell carcinomas. Tumour Biol 2010, 31:141-147.
42. Heider K.H., Kuthan H., Stehle G., Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 2004, 53:567-579.
43. Heider K.H., Sproll M., Susani S., Patzelt E., Beaumier P., Ostermann E., et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996, 43:245-253.
44. de Bree R., Roos J.C., Plaizier M.A., Quak J.J., van Kamp G.J., den Hollander W., et al. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Br J Cancer 1997, 75:1049-1060.
45. de Bree R., Roos J.C., Quak J.J., den Hollander W., Snow G.B., van Dongen G.A. Radioimmunoscintigraphy and biodistribution of technetium-99 m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995, 1:591-598.
46. Colnot D.R., Ossenkoppele G.J., Roos J.C., Quak J.J., de Bree R., Borjesson P.K., et al. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Re-labeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 2002, 8:3401-3406.
47. Colnot D.R., Quak J.J., Roos J.C., van Lingen A., Wilhelm A.J., van Kamp G.J., et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000, 41:1999-2010.
48. Nestor M., Persson M., van Dongen G.A., Jensen H.J., Lundqvist H., Anniko M., et al. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2005, 32:1296-1304.
49. Andersson H., Elgqvist J., Horvath G., Hultborn R., Jacobsson L., Jensen H., et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res 2003, 9:3914S-3921S.
50. Hadley S.W., Wilbur D.S., Gray M.A., Atcher R.W. Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate. Bioconjug Chem 1991, 2:171-179.
51. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
52. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787-2799.
53. Brakenhoff R.H., van Gog F.B., Looney J.E., van Walsum M., Snow G.B., van Dongen G.A. Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol Immunother 1995, 40:191-200.
54. Schrijvers A.H., Quak J.J., Uyterlinde A.M., van Walsum M., Meijer C.J., Snow G.B., et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993, 53:4383-4390.
55. Sjöström A., Tolmachev V., Lebeda O., Koziorowski J., Carlsson J., Lundqvist H. Direct astatination of a tumour-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group. J Radioanal Nucl Chem 2003, 256:191-197.
56. Koziorowski J., Henssen C., Weinreich R. A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for radioiodination of proteins. Appl Radiat Isot 1998, 49:955-959.
57. Langer C.J. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 2008, 112:2635-2645.
58. Raben D., Helfrich B., Chan D.C., Ciardiello F., Zhao L., Franklin W., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005, 11:795-805.
59. Kim Y., Lee Y.S., Choe J., Lee H., Kim Y.M., Jeoung D. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 2008, 283:22513-22528.
60. Wang S.J., Bourguignon L.Y. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132:771-778.
61. Palyi-Krekk Z., Barok M., Kovacs T., Saya H., Nagano O., Szollosi J., et al. EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett 2008, 263:231-242.
62. Milas L., Fang F.M., Mason K.A., Valdecanas D., Hunter N., Koto M., et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007, 67:568-572.
63. Nasu S., Ang K.K., Fan Z., Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001, 51:474-477.